Pitout JD, Laupland KB: Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008, 8: 159-166. 10.1016/S1473-3099(08)70041-0.
Article
CAS
PubMed
Google Scholar
Apisarnthanarak A, Kiratisin P, Mundy LM: Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2008, 29: 671-674. 10.1086/588082.
Article
PubMed
Google Scholar
Kang CI, Cheong HS, Chung DR, Peck KR, Song JH, Oh MD, et al: Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis. 2008, 27: 85-88. 10.1007/s10096-007-0401-6.
Article
PubMed
Google Scholar
Coque TM, Baquero F, Canton R: Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 2008, 13:
Google Scholar
Jones RN, Jenkins SG, Hoban DJ, Pfaller MA, Ramphal R: In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. Int J Antimicrob Agents. 2000, 15: 111-118. 10.1016/S0924-8579(00)00152-7.
Article
CAS
PubMed
Google Scholar
Winokur PL, Canton R, Casellas JM, Legakis N: Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis. 2001, 32 (Suppl 2): S94-103. 10.1086/320182.
Article
CAS
PubMed
Google Scholar
Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y: High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2005, 49: 2137-2139. 10.1128/AAC.49.5.2137-2139.2005.
Article
CAS
PubMed Central
PubMed
Google Scholar
Kim BN, Woo JH, Kim MN, Ryu J, Kim YS: Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect. 2002, 52: 99-106. 10.1053/jhin.2002.1288.
Article
PubMed
Google Scholar
Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO: Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001, 32: 1162-1171. 10.1086/319757.
Article
CAS
PubMed
Google Scholar
Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y: Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006, 50: 1257-1262. 10.1128/AAC.50.4.1257-1262.2006.
Article
CAS
PubMed Central
PubMed
Google Scholar
Schwaber MJ, Carmeli Y: Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007, 60: 913-920. 10.1093/jac/dkm318.
Article
CAS
PubMed
Google Scholar
Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD: Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect. 2008, 14: 1041-1047. 10.1111/j.1469-0691.2008.02089.x.
Article
CAS
PubMed
Google Scholar
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005, 43: 1130-1139. 10.1097/01.mlr.0000182534.19832.83.
Article
PubMed
Google Scholar
Quan H, Li B, Saunders LD, Parsons GA, Nilsson CI, Alibhai A, et al: Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res. 2008, 43: 1424-1441. 10.1111/j.1475-6773.2007.00822.x.
Article
PubMed Central
PubMed
Google Scholar
Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA: New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004, 57: 1288-1294. 10.1016/j.jclinepi.2004.03.012.
Article
PubMed
Google Scholar
Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S: An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer. 2004, 4: 94-10.1186/1471-2407-4-94.
Article
PubMed Central
PubMed
Google Scholar
Parkins MD, Sabuda DM, Elsayed S, Laupland KB: Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother. 2007, 60: 613-618. 10.1093/jac/dkm212.
Article
CAS
PubMed
Google Scholar
Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing. 18th informational supplement M100-S18. 2009. 2008, Wayne, CLSI
Google Scholar
Pitout JD, Church DL, Gregson DB, Chow BL, McCracken M, Mulvey MR, et al: Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. Antimicrob Agents Chemother. 2007, 51: 1281-1286. 10.1128/AAC.01377-06.
Article
CAS
PubMed Central
PubMed
Google Scholar
Pitout JD, Hamilton N, Church DL, Nordmann P, Poirel L: Development and clinical validation of a molecular diagnostic assay to detect CTX-M-type beta-lactamases in Enterobacteriaceae. Clin Microbiol Infect. 2007, 13: 291-297. 10.1111/j.1469-0691.2006.01645.x.
Article
CAS
PubMed
Google Scholar
Pitout JD, Gregson DB, Campbell L, Laupland KB: Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother. 2009, 53: 2846-2851. 10.1128/AAC.00247-09.
Article
CAS
PubMed Central
PubMed
Google Scholar
Pitout JD, Hanson ND, Church DL, Laupland KB: Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis. 2004, 38: 1736-1741. 10.1086/421094.
Article
CAS
PubMed
Google Scholar
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006, 34: 1589-1596. 10.1097/01.CCM.0000217961.75225.E9.
Article
PubMed
Google Scholar
Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D: Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003, 115: 529-535. 10.1016/j.amjmed.2003.07.005.
Article
PubMed
Google Scholar
Burgess DS, Hall RG, Lewis JS, Jorgensen JH, Patterson JE: Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy. 2003, 23: 1232-1237. 10.1592/phco.23.12.1232.32706.
Article
CAS
PubMed
Google Scholar
Paterson DL, Ko WC, von GA, Mohapatra S, Casellas JM, Goossens H, et al: Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004, 39: 31-37. 10.1086/420816.
Article
CAS
PubMed
Google Scholar
Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO: Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis. 2001, 33: 1288-1294. 10.1086/322667.
Article
CAS
PubMed
Google Scholar
Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO: Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis. 2005, 41: 923-929. 10.1086/432940.
Article
CAS
PubMed
Google Scholar
Endimiani A, Luzzaro F, Perilli M, Lombardi G, Coli A, Tamborini A, et al: Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis. 2004, 38: 243-251. 10.1086/380645.
Article
CAS
PubMed
Google Scholar